CAMBRIDGE, Mass., June 7 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) today announced that it will present at The Wall Street
Analyst Forum - 17th Annual Analyst Conference on Wednesday, June 14, 2006,
at 10:30 a.m. EDT. The analyst and investor conference is being held at the
Princeton Club in New York City. A live webcast will be available online
via the Investor Relations section of Biopure's web site at
http://www.biopure.com or at
http://www.investorcalendar.com/CEPage.asp?ID=104919 . An archive of the
presentation will be available for at least two weeks.
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. Biopure plans to
apply in Europe, in mid 2006, for regulatory approval of a proposed
surgical anemia indication. The company is developing Hemopure for a
potential indication in cardiovascular ischemia, in addition to supporting
the U.S. Navy's government-funded efforts to develop a potential
out-of-hospital trauma indication. The company's veterinary product
Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only
oxygen therapeutic approved by the U.S. Food and Drug Administration and
the European Commission, is indicated for the treatment of anemia in dogs.
Statements in this announcement that are not strictly historical are
forward-looking statements. Actual results and their timing may differ
materially from those projected in these forward-looking statements due to
risks and uncertainties. These risks include, without limitation,
uncertainties regarding the company's financial position, unexpected costs
and expenses, delays and determinations by regulatory authorities,
unanticipated problems with the product's commercial use, whether or not
product related, and with product distributors, sales agents or other third
parties, and delays in or unpredictable outcomes of clinical trials. The
company undertakes no obligation to release publicly the results of any
revisions to these forward- looking statements to reflect events or
circumstances arising after the date hereof. A full discussion of the
company's operations and financial condition can be found in the company's
filings with the U.S. Securities and Exchange Commission, including under
the heading "Risk Factors" in the Form 10-Q filed on March 13, 2006, which
can be accessed in the EDGAR database at the SEC Web site,
http://www.sec.gov. The content of this announcement does not necessarily
reflect the position or the policy of the U.S. Government or the Department
of Defense, and no official endorsement should be inferred.
Contact:
Douglas Sayles Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Douglas Sayles of Biopure Corporation,
+1-617-234-6826, IR@biopure.com; Investors, Herb Lanzet of H.L.
Lanzet Inc. for Biopure Corporation, +1-212-888-4570,
lanzet@aol.com
|
